Clinical trial · Expanded Access
Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)
NCT01825395CI-TRIAL-000543203 4-DAPapproved for marketingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lambert Eaton Myasthenic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3, 4-Diaminopyridine | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age 18 years or older, * Diagnosed with LEMS, * If female, have a negative pregnancy test, and * If premenopausal, be willing to practice an effective form of birth control during the study, * Tested and found by ECG not to have a prolonged QT syndrome, * Agree to have a second ECG at the time of peak drug effect, * Has understood and signed the Informed Consent. Exclusion Criteria: * Is known to have a sensitivity to 3, 4-DAP, * Has a history of: 1. past or current seizures, 2. cardiac arrhythmia, 3. hepatic, renal or hematologic disease, or 4. severe asthma, * Is believed by the investigator to be unable to comply with the protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.